Boston Scientific (BSX) Enterprise Value (2009 - 2026)

Boston Scientific (BSX) has 18 years of Enterprise Value data on file, last reported at -$1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 146.54% year-over-year to -$1.2 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.2 billion (down 146.54% YoY), and the FY2025 full-year result was -$1.7 billion, down 362.73% from the prior year.
• Enterprise Value climbed to -$1.2 billion in Q1 2026, from -$1.7 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$167.0 million in Q2 2023 to a low of -$2.7 billion in Q2 2024.
• A 5-year average of -$931.1 million and a median of -$617.0 million in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 89.68% in 2022 and slumped 1501.8% in 2024, its largest moves.
• Tracing BSX's Enterprise Value over 5 years: stood at -$928.0 million in 2022, then soared by 33.51% to -$617.0 million in 2023, then surged by 39.55% to -$373.0 million in 2024, then sank by 362.73% to -$1.7 billion in 2025, then grew by 29.72% to -$1.2 billion in 2026.
• Business Quant data shows BSX's Enterprise Value at -$1.2 billion in Q1 2026, -$1.7 billion in Q4 2025, and -$1.0 billion in Q3 2025.